<?xml version='1.0' encoding='utf-8'?>
<document id="30479035"><sentence text="Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction."><entity charOffset="35-45" id="DDI-PubMed.30479035.s1.e0" text="aprepitant" /><entity charOffset="50-55" id="DDI-PubMed.30479035.s1.e1" text="opium" /><pair ddi="false" e1="DDI-PubMed.30479035.s1.e0" e2="DDI-PubMed.30479035.s1.e0" /><pair ddi="false" e1="DDI-PubMed.30479035.s1.e0" e2="DDI-PubMed.30479035.s1.e1" /></sentence><sentence text="Polypharmacy of elderly oncology patients and fragmented medication management are well-known risk factors for drug-drug interactions (DDIs)" /><sentence text=" These interactions can occur among antineoplastic, ongoing chronic treatment(s) and chemotherapy-associated treatments, like antiemetics" /><sentence text=" Clinically relevant interactions based on enzyme- or transporter-inhibition phenomena of active drugs can increase the frequency of their DDIs" /><sentence text=" We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations"><entity charOffset="71-81" id="DDI-PubMed.30479035.s5.e0" text="aprepitant" /><entity charOffset="86-91" id="DDI-PubMed.30479035.s5.e1" text="opium" /><pair ddi="false" e1="DDI-PubMed.30479035.s5.e0" e2="DDI-PubMed.30479035.s5.e0" /><pair ddi="false" e1="DDI-PubMed.30479035.s5.e0" e2="DDI-PubMed.30479035.s5.e1" /></sentence><sentence text=" We discuss this DDI's hypothetical pharmacological mechanisms and management" /><sentence text="" /></document>